M&A / Deals Gilead inks $140M API supply deal, tightening ties to Korean manufacturer BioSpaceThe agreement is the largest in a series of deals that Gilead Sciences has penned with Korea's Yuhan.Read full story pharminent May 22, 2026 (Last updated: May 22, 2026) BioSpace The agreement is the largest in a series of deals that Gilead Sciences has penned with Korea’s Yuhan. Read full story Post navigation Previous: GBL joins CVC in 10.7bn takeover bid for RecordatiNext: Kelun-Merck validate TROP2-Keytruda pairing in lung cancer with improved survival Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026